CTTQ’s HER2 Bispecific ADC TQB2102 Hits Phase 3 Endpoints in HER2-Low Breast Cancer, Setting Up China Filing
Chia Tai Tianqing Pharmaceutical Group (CTTQ), a core subsidiary of Sino Biopharmaceutical, has reported a major late-stage clinical win for TQB2102 (rolditamig deuderuxtecan), its internally developed HER2 bispecific antibody-drug conjugate (ADC). The…
Chia Tai Tianqing Pharma (CTTQ)
Innovating for Life, Creating Greater Health Value